Use of U.S. Blood Donors for National Serosurveillance of SARS-CoV-2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program.
Mars StoneClara Di GermanioDavid J WrightHasan SulaemanHoney DaveRebecca V FinkEdward P NotariValerie GreenDonna StraussDebbie KesslerMark DestreePaula SaaPhillip C WilliamsonGraham SimmonsSusan L StramerJean OpsomerJefferson M JonesSteven KleinmanMichael P Buschnull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Increases in seroprevalence were found in all regions, with the largest increase in New York. Seroprevalence was higher in non-Hispanic Black and Hispanic blood donors than in non-Hispanic White blood donors. SARS-CoV-2 antibody testing of blood donor samples can be used to estimate the seroprevalence in the general population by region and demographic group. The methods derived from the RESPONSE seroprevalence study served as the basis for expanding SARS-CoV-2 seroprevalence surveillance to all 50 states and Puerto Rico.